Detecting 2-Hydroxyglutarate

Two enantiomers, one oncometabolite.

Why Enantiomers Matter

SpeciesSourceAssociation
D-2-HG (R)Neomorphic IDH1/2 mutations; also minor normal productionOncogenic; accumulates to millimolar in IDH-mutant tumours
L-2-HG (S)Normal TCA by-product; accumulates in L2HGDH deficiencyNeurological disease, not typically oncogenic

Important distinction. Achiral LC-MS reports the sum. In IDH-mutant cells the D form dominates so the sum is a reasonable proxy; in IDH-wild-type cells with an acquired metabolic shift the two can move in opposite directions, and the sum is uninterpretable. The appropriate method is chiral.

Part 1 — Methods

MethodEnantiomer resolutionSensitivityNote
Chiral LC-MS/MS (chiral stationary phase)YesHighThe reference approach
Achiral LC-MS/MSNoHighAdequate only when D dominates
Derivatisation with chiral reagent (e.g. DATAN)YesHighConverts enantiomers to diastereomers, separable on C18
GC-MS with chiral columnYesHighRequires derivatisation
Enzymatic assay (D-2-HGDH)Yes, D-specificModerateUseful for confirmation
Magnetic resonance spectroscopy (in vivo)NoLowReports total 2-HG; used clinically

Readout note. The derivatisation approach — reacting 2-HG with a chiral anhydride to form diastereomers — allows separation on a conventional reverse-phase column, which is practical for laboratories without chiral columns. The derivatisation must go to completion, and the reagent must be enantiopure; a partially racemic reagent produces doubled peaks that are easily misread.

Part 2 — Sample Handling

StepRequirementConsequence if omitted
QuenchCold, immediate2-HG is relatively stable but its precursors are not
ExtractionCold aqueous or organic; avoid strong acidAcid can lactonise related metabolites
Internal standardIsotope-labelled 2-HG, added before extractionRecovery unmeasured
Storage−80 °C; avoid repeated freeze–thawDrift between runs
Medium measurementInclude medium blankSerum and medium contribute low levels
NormalisationCell number or protein, statedComparisons across conditions distorted

Caveat on tissue. In tissue, 2-HG is present at different concentrations in tumour and stroma, and bulk measurement averages them. An IDH-mutant tumour with 30% tumour cellularity reports a much lower concentration than the tumour cells actually contain — a point that matters when comparing to in vitro thresholds.

Part 3 — Interference

InterferenceDetail
Isobaric compoundsGlutamate and other metabolites can share transition masses; chromatographic separation is required
Matrix effectsMedium and serum suppress ionisation differently from standards in water
Enantiomer cross-talkIncomplete separation produces a shoulder that inflates the minor enantiomer
Derivatisation by-productsAdditional peaks that can co-elute
Sample carry-over2-HG sticks to some column chemistries

Part 4 — What the Measurement Supports

ClaimRequiresNot sufficient
"IDH mutation produces D-2-HG"Enantiomer-resolved measurement, mutant versus wild-typeTotal 2-HG
"2-HG is elevated in this model"D-2-HG with a wild-type comparatorA single arm
"2-HG inhibits TET in these cells"Concentration plus an epigenetic readoutConcentration alone
"The inhibitor reduced 2-HG"Enantiomer-resolved measurement before and afterTotal 2-HG
"2-HG is a biomarker in vivo"MRS or biofluid measurement with validationCell culture data

Part 5 — Common Failures

  • • Total 2-HG reported for an IDH-wild-type model.
  • • Chiral separation claimed without demonstrating resolution of standards.
  • • No internal standard, so recovery and matrix effects are unmeasured.
  • • Achiral method used to compare enantiomer ratios.
  • • Medium contribution not subtracted.
  • • Bulk tissue compared with cell-culture thresholds without correcting for cellularity.
  • • MRS values compared directly with LC-MS values, although they measure different volumes and report total 2-HG.
  • • Inhibitor effect measured at a single timepoint, before the pool has re-equilibrated.

Part 6 — Where This Article Connects

This is the analytical companion to the oncometabolite article, which covers the dioxygenase logic and the epigenetic readouts. It connects to the succinate model article, where the same compartment problem arises, and to the tracing article, where 2-HG can be followed from labelled glutamine.

If you need 2-HG measured with enantiomer resolution and matrix-matched standards, we can scope the analysis with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

2-HG concentration, enantiomer ratio and recovery vary with genotype, matrix, extraction and method. Chiral resolution must be demonstrated for each method.

A total 2-HG value does not establish the D-enantiomer concentration, and an elevated concentration does not establish dioxygenase inhibition in the cell.

Scientific interpretation and experimental design

  • • Two enantiomers, one oncometabolite. Resolve them.
  • • Demonstrate the separation. Standards, not assumptions.
  • • Matrix-match the standard curve.
  • • Subtract the medium.
  • • Tissue averages tumour and stroma.
  • • MRS reports total, not D.

Selected references for further reading

  • • Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744.
  • • Struys EA, et al. Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography–tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. Clinical Chemistry. 2004;50:1391–1395.
  • • Andronesi OC, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Science Translational Medicine. 2012;4:116ra4.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: